Flupentixol%25252525252525252525252525252520and%25252525252525252525252525252520melitracen

# Flupentixol and Melitracen ## Overview Flupentixol is a thioxanthene antipsychotic, and melitracen is a tricyclic antidepressant. This combination is often used for anxiety and depression. ## Primary Indications * Anxiety and depression, particularly when co-occurring. * Depressive neuroses. ## Adult Dosing * **Typical Starting Dose:** 1 tablet (containing 0.5 mg flupentixol and 10 mg melitracen) twice daily. * **Maintenance Dose:** 1 tablet three times daily or 2 tablets twice daily. * **Maximum Dose:** 6 tablets daily (3 mg flupentixol and 60 mg melitracen). *Note: Dosing is typically adjusted based on individual patient response and tolerability. Specific titration schedules may vary.* ## Pediatric Dosing * Safety and efficacy in pediatric patients have not been established. Use is not recommended. ## Dose Adjustments * **Hepatic Impairment:** Caution is advised. Lower doses may be necessary. * **Renal Impairment:** No specific dose adjustments are routinely recommended, but caution is advised. * **Elderly:** Lower doses may be considered, especially at the initiation of therapy, due to potential increased sensitivity. ## Contraindications * Hypersensitivity to flupentixol, melitracen, or any excipient. * Circulatory collapse. * Marked impairment of liver function. * Severe renal impairment. * Aggressive behavior or excessive psychomotor agitation. * Bone marrow depression. * Untreated narrow-angle glaucoma. * Concomitant use with MAOIs or within 14 days of discontinuing MAOIs (due to risk of serotonin syndrome or hypertensive crisis). * Recent myocardial infarction. ## Adverse Effects * **Common:** Sedation, dizziness, dry mouth, constipation, blurred vision, sweating, tremor, insomnia, headache, fatigue. * **Less Common/Serious:** Anticholinergic effects (urinary retention, confusion), orthostatic hypotension, tachycardia, ECG changes, extrapyramidal symptoms (though less common with low-dose flupentixol), potential for weight gain, sexual dysfunction. * **Rare:** Neuroleptic Malignant Syndrome (NMS), blood dyscrasias, seizures, increased intraocular pressure. ## Key Drug Interactions * **MAOIs:** Increased risk of serotonin syndrome or hypertensive crisis. * **CNS Depressants (e.g., alcohol, benzodiazepines, opioids):** Additive sedative effects. * **Anticholinergic Agents:** Additive effects, increasing risk of anticholinergic adverse events. * **Antihypertensives:** May reduce the effectiveness of antihypertensive medications. * **Drugs Prolonging QT Interval:** Increased risk of cardiac arrhythmias. * **CYP2D6 Inhibitors:** May increase flupentixol levels. ## Monitoring * **Clinical Response:** Assess for improvement in symptoms of anxiety and depression. * **Adverse Effects:** Monitor for sedation, anticholinergic effects, orthostatic hypotension, and extrapyramidal symptoms. * **ECG:** May be considered in patients with risk factors or prior cardiac history, especially with higher doses or combination with other QT-prolonging drugs. * **Blood Counts:** Consider periodically, especially in patients with a history of hematological abnormalities. ## Clinical Pearls * This combination aims to treat both anxiety and underlying depressive symptoms. * Initiate therapy at a low dose and titrate slowly based on response and tolerability. * Due to the anticholinergic properties, caution patients regarding activities requiring mental alertness (e.g., driving) until tolerance is established. * Advise patients to avoid alcohol during treatment. * Withdrawal symptoms may occur upon abrupt discontinuation; gradual tapering is recommended. *** **Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and local guidelines for definitive treatment decisions.